The role of interleukin-6 in pulmonary and systemic manifestations in a murine model of chronic obstructive pulmonary disease

Experimental Lung Research

Volumn 36, Issue 8, 2010, Pages 469-483

  Pauwels, Nele S ^a   Bracke, Ken R ^a   Maes, Tania ^a   Pilette, Charles ^b   Joos, Guy F ^a   Brusselle, Guy G ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

COPD; interleukin 6; pulmonary inflammation; systemic inflammation

Indexed keywords

CIGARETTE SMOKE; INTERLEUKIN 6; LEPTIN; MESSENGER RNA;

ACUTE PHASE RESPONSE; ADIPOSE TISSUE; AIR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CELL AGGREGATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; EMPHYSEMA; IMMUNOGLOBULIN BLOOD LEVEL; IN VIVO STUDY; INFLAMMATORY CELL; KNOCKOUT MOUSE; LUNG; LUNG LAVAGE; LUNG PARENCHYMA; LYMPHOID CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; WEIGHT GAIN; WILD TYPE;

ADIPOSE TISSUE, WHITE; ANIMALS; BRONCHOALVEOLAR LAVAGE FLUID; CELL COUNT; CYTOKINES; DISEASE MODELS, ANIMAL; GENE EXPRESSION; INTERLEUKIN-6; LEPTIN; LUNG; LYMPHOCYTES; MALE; MICE; MICE, KNOCKOUT; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PULMONARY EMPHYSEMA; RNA, MESSENGER; SMOKING; TOBACCO SMOKE POLLUTION;

EID: 77958008431     PISSN: 01902148     EISSN: 15210499     Source Type: Journal    
DOI: 10.3109/01902141003739723     Document Type: Article

References (49)

1. Pauwels RA, Rabe KF: Burden and clinical features of chronic obstructive pulmonary disease (COPD). Lancet. 2004;364: 613-620.
2. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, et al.: Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2007;176: 532-555.
3. Hogg JC, Chu F, Utokaparch S, Woods R, Elliott WM, Buzatu L, et al.: The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med. 2004;350: 2645-2653.
4. Agusti AG: Systemic effects of chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2005;2: 367-370.
5. Nishimoto N, Kishimoto T: Interleukin 6: from bench to bedside. Nat Clin Pract Rheumatol. 2006;2: 619-626.
6. Xing Z, Gauldie J, Cox G, Baumann H, Jordana M, Lei XF, et al.: IL-6 is an antiinfammatory cytokine required for controlling local or systemic acute infammatory responses. J Clin Invest. 1998;101: 311-320.
7. Hirano T, Yasukawa K, Harada H, Taga T, Watanabe Y, Matsuda T, et al.: Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce im-munoglobulin. Nature. 1986;324: 73-76.
8. Maggio M, Guralnik JM, Longo DL, Ferrucci L: Interleukin-6 in aging and chronic disease: a magnifcent pathway. J Gerontol A Biol Sci Med Sci. 2006;61: 575-584.
9. Gabay C: Interleukin-6 and chronic infammation. Arthritis Res Ther. 2006;8(Suppl 2):S3.
10. Mohamed-Ali V, Goodrick S, Rawesh A, Katz DR, Miles JM, Yudkin JS, et al.: Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab. 1997;82: 4196-4200.
11. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Muller-Newen G, Schaper F: Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J. 2003;374: 1-20.
12. Jones SA: Directing transition from innate to acquired immunity: defning a role for IL-6. J Immunol. 2005;175: 3463-3468.
13. Quinton LJ, Jones MR, Robson BE, Simms BT, Whitsett JA, Mizgerd JP: Alveolar epithelial STAT3, IL-6 family cytokines, and host defense during Escherichia coli pneumonia. Am J Respir Cell Mol Biol. 2008;38: 699-706.
14. Bhowmik A, Seemungal TA, Sapsford RJ, Wedzicha JA: Relation of sputum infammatory markers to symptoms and lung function changes in COPD exacerbations. Thorax. 2000;55: 114-120.
15. Song W, Zhao J, Li Z: Interleukin-6 in bronchoalveolar lavage fuid from patients with COPD. Chin Med J (Engl ). 2001;114: 1140-1142.
16. Bucchioni E, Kharitonov SA, Allegra L, Barnes PJ: High levels of interleukin-6 in the exhaled breath condensate of patients with COPD. Respir Med. 2003;97: 1299-1302.
17. Van Durme YM, Verhamme KM, Aarnoudse AJ, Van Pottel-berge GR, Hofman A, Witteman JC, et al.: C-reactive protein levels, haplotypes, and the risk of incident chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2009;179: 375-382.
18. Dahl M, Vestbo J, Lange P, Bojesen SE, Tybjaerg-Hansen A, Nordestgaard BG: C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007;175: 250-255.
19. Gan WQ, Man SF, Senthilselvan A, Sin DD: Association between chronic obstructive pulmonary disease and systemic infammation: a systematic review and a meta-analysis. Thorax. 2004;59: 574-580.
20. Doz E, Noulin N, Boichot E, Guenon I, Fick L, Le BM, et al.: Cigarette smoke-induced pulmonary infammation is TLR4/MyD88 and IL-1R1/MyD88 signaling dependent. J Immunol. 2008;180: 1169-1178.
21. Kopf M, Baumann H, Freer G, Freudenberg M, Lamers M, Kishimoto T, et al.: Impaired immune and acute-phase responses in interleukin-6-defcient mice. Nature. 1994;368: 339-342.
22. D'hulst AI, Vermaelen KY, Brusselle GG, Joos GF, Pauwels RA: Time course of cigarette smoke-induced pulmonary infammation in mice. Eur Respir J. 2005;26: 204-213.
23. Bracke KR, D hulst AI, Maes T, Demedts IK, Moer-loose KB, Kuziel WA, et al.: Cigarette smoke-induced pulmonary infammation, but not airway remodeling, is attenuated in chemokine receptor 5-defcient mice. Clin Exp Allergy. 2007;37: 1467-1479.
24. Vermaelen KY, Carro-Muino I, Lambrecht BN, Pauwels RA: Specifc migratory dendritic cells rapidly transport antigen from the airways to the thoracic lymph nodes. J Exp Med. 2001;193: 51-60.
25. Vermaelen K, Pauwels R: Accurate and simple discrimination of mouse pulmonary dendritic cell and macrophage populations by fow cytometry: methodology and new insights. Cytometry A. 2004;61: 170-177.
26. Thurlbeck WM: Measurement of pulmonary emphysema. Am Rev Respir Dis. 1967;95: 752-764.
27. D'hulst AI, Maes T, Bracke KR, Demedts IK, Tournoy KG, Joos GF, et al.: Cigarette smoke-induced pulmonary emphysema in scid-mice. Is the acquired immune system required? Respir Res. 2005;6: 147.
28. Wigmore SJ, Fearon KC, Maingay JP, Lai PB, Ross JA: Interleukin-8 can mediate acute-phase protein production by isolated human hepatocytes. Am J Physiol. 1997;273: E720-E726.
29. D'hulst AI, Bracke KR, Maes T, De Bleecker JL, Pauwels RA, Joos GF, et al.: Role of tumour necrosis factor-alpha receptor p75 in cigarette smoke-induced pulmonary infammation and emphysema. Eur Respir J. 2006;28: 102-112.
30. La Cava A, Matarese G: The weight of leptin in immunity. Nat Rev Immunol. 2004;4: 371-379.
31. Yu M, Zheng X, Witschi H, Pinkerton KE: The role of interleukin-6 in pulmonary infammation and injury induced by exposure to environmental air pollutants. Toxicol Sci. 2002;68: 488-497.
32. Demoor T, Bracke KR, Maes T, Vandooren B, Elewaut D, Pilette C, et al.: Role of lymphotoxin-alpha in cigarette smoke-induced infammation and lymphoid neogenesis. Eur Respir J. 2009;34: 405-416.
33. Demoor T, Bracke KR, Vermaelen KY, Dupont L, Joos GF, Brusselle GG: CCR7 modulates pulmonary and lymph node infammatory responses in cigarette smoke-exposed mice. J Immunol. 2009;183: 8186-8194.
34. Bao S, Husband AJ, Beagley KW: B1 B cell numbers and antibodies against phosphorylcholine and LPS are increased in IL-6 gene knockout mice. Cell Immunol. 1999;198: 139-142.
35. Rose-John S, Scheller J, Elson G, Jones SA: Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in infammation and cancer. J Leukoc Biol. 2006;80: 227-236.
36. Wouters EF, Creutzberg EC, Schols AM: Systemic effects in COPD. Chest. 2002;121: 127S-130S.
37. Sethi S, Murphy TF: Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med. 2008;359: 2355-2365.
38. Fattori E, Cappelletti M, Costa P, Sellitto C, Cantoni L, Carelli M, et al.: Defective infammatory response in interleukin 6-defcient mice. J Exp Med. 1994;180: 1243-1250.
39. Gosker HR, Langen RC, Bracke KR, Joos GF, Brusselle GG, Steele C, et al.: Extrapulmonary manifestations of COPD in a mouse model of chronic cigarette smoke exposure. Am J Respir Cell Mol Biol. 2008;40: 710-716.
40. Fäldt J, Wernstedt I, Fitzgerald SM, Wallenius K, Bergstrom G, Jansson JO: Reduced exercise endurance in interleukin-6-defcient mice. Endocrinology. 2004;145: 2680-2686.
41. Wallenius V, Wallenius K, Ahren B, Rudling M, Carlsten H, Dickson SL, et al.: Interleukin-6-defcient mice develop mature-onset obesity. Nat Med. 2002;8: 75-79.
42. Di Gregorio GB, Hensley L, Lu T, Ranganathan G, Kern PA: Lipid and carbohydrate metabolism in mice with a targeted mutation in the IL-6 gene: absence of development of age-related obesity. Am J Physiol Endocrinol Metab. 2004;287: E182-E187.
43. Hoene M, Weigert C: The role of interleukin-6 in insulin resistance, body fat distribution and energy balance. Obes Rev. 2008;9: 20-29.
44. Hata H, Sakaguchi N, Yoshitomi H, Iwakura Y, Sekikawa K, Azuma Y, et al.: Distinct contribution of IL-6, TNF-alpha, IL-1, and IL-10 to T cell-mediated spontaneous autoimmune arthritis in mice. J Clin Invest. 2004;114: 582-588.
45. Yamamoto M, Yoshizaki K, Kishimoto T, Ito H: IL-6 is required for the development of Th1 cell-mediated murine colitis. J Immunol. 2000;164: 4878-4882.
46. Atreya R, Mudter J, Finotto S, Mullberg J, Jostock T, Wirtz S, et al.: Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal infammation: evidence in crohn disease and experimental colitis in vivo. Nat Med. 2000;6: 583-588.
47. Nishimoto N, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Azuma J: Long-term safety and effcacy of tocilizumab, an anti-interleukin-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and effcacy in a 5-year extension study. Ann Rheum Dis. 2008;68: 1580-1584.
48. Ito H, Takazoe M, Fukuda Y, Hibi T, Kusugami K, Andoh A, et al.: A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn s disease. Gastroenterology. 2004;126: 989-996.
49. Barnes PJ: Emerging pharmacotherapies for COPD. Chest. 2008;134: 1278-1286.